GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2012

CE Mark for Rapid Acute Kidney Injury Test

  • Astute Medical’s NephroCheck™ test has received a CE mark for commercialization in Europe. The cartridge-based sandwich immunoassay test, run on the firm’s Astute140™ Meter, quantitatively measures two validated urinary biomarkers as a risk assessment for acute kidney injury (AKI), and provides results in 20 minutes.

    Biomarker firm Astute’s strategy is to first identify clinical opportunities for biomarker discovery through collaboration with the clinical community. The firm then takes a systems biology approach to the discovery process, combining pathway analysis, proteomics, and genomics to identify and validate biomarkers for the disease and target patient population.

    Computational techniques are then used to optimize the selection of individual biomarkers and the performance of biomarker panels, prior to undertaking larger, multisite validation studies to confirm and extend data from pilot studies. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?